Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.84 USD | +4.12% | -7.70% | +142.35% |
13/05 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
08/05 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+142.35% | 610M | |
+25.99% | 49.18B | |
+0.82% | 42.11B | |
+49.96% | 40.37B | |
-5.26% | 28.85B | |
+13.24% | 26.09B | |
-22.21% | 18.71B | |
+8.54% | 13.26B | |
+32.25% | 12.32B | |
+0.30% | 11.99B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Oppenheimer Initiates Coverage on Mind Medicine With Outperform Rating, $3.50 Price Target